The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane.
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Pertuzumab (Primary) ; Taxanes (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Pharmacodynamics
- Acronyms REVER
- 02 Dec 2019 Status changed from not yet recruiting to recruiting.
- 28 Mar 2019 Planned initiation date changed from 1 Sep 2018 to 1 Mar 2019.
- 14 Aug 2018 New trial record